This Issue At A Glance

Tozer et al (p. 2029) evaluated the effectiveness of rescue therapy in eyes with neovascular age-related macular degeneration (AMD) that failed monotherapy with intravitreal injections of bevacizumab or ranibizumab. They found that the combination of photodynamic therapy (PDT) and injections of anti–vascular endothelial growth factor (VEGF) agents resulted in improvements in visual acuity, central retinal thickness, number of fluid-free visits, and the length of time between treatments. In this retrospective, noncomparative, interventional case series, 26 eyes of 26 patients were identified as having had both PDT and anti-VEGF injections within a 7-day period. After the initiation of combination therapy, statistically significant improvements in visual acuity were seen at the 1- and 3-month marks; significant decreases in central subfield retinal thickness were seen at 1, 3, and 6 months; and the number of visits with no subretinal fluid increased from 0.5% to 45%. Overall, the interval between treatments increased from once every 1.6 months before combination therapy to once every 2.7 months afterward.